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IMPORTANCE—The disease process leading to clinical type 1 diabetes often starts during the 
first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell 
autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do 
not contain intact proteins.
OBJECTIVE—To test the hypothesis that weaning to an extensively hydrolyzed formula 
decreases the cumulative incidence of diabetes-associated autoantibodies in young children.
DESIGN, SETTING, AND PARTICIPANTS—A double-blind randomized clinical trial of 2159 
infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes 
recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1078 were 
randomized to be weaned to the extensively hydrolyzed casein formula and 1081 were randomized 
to be weaned to a conventional cows’ milk–based formula. The participants were observed to 
April 16, 2013.
INTERVENTIONS—The participants received either a casein hydrolysate or a conventional 
cows’ milk formula supplemented with 20% of the casein hydrolysate.
MAIN OUTCOMES AND MEASURES—Primary outcome was positivity for at least 2 
diabetes-associated autoantibodies out of 4 analyzed. Autoantibodies to insulin, glutamic acid 
decarboxylase, and the insulinoma-associated–2 (IA-2) molecule were analyzed using 
radiobinding assays and islet cell antibodies with immunofluorescence during a median 
observation period of 7.0 years (mean, 6.3 years).
RESULTS—The absolute risk of positivity for 2 or more islet autoantibodies was 13.4% among 
those randomized to the casein hydrolysate formula (n = 139) vs 11.4% among those randomized 
to the conventional formula (n = 117). The unadjusted hazard ratio for positivity for 2 or more 
autoantibodies among those randomized to be weaned to the casein hydrolysate was 1.21 (95% CI, 
0.94–1.54), compared with those randomized to the conventional formula, while the hazard ratio 
adjusted for HLA risk, duration of breastfeeding, vitamin D use, study formula duration and 
consumption, and region was 1.23 (95% CI, 0.96–1.58). There were no clinically significant 
differences in the rate of reported adverse events between the 2 groups.
CONCLUSIONS AND RELEVANCE—Among infants at risk for type 1 diabetes, the use of a 
hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of 
diabetes-associated autoantibodies after 7 years. These findings do not support a benefit from 
hydrolyzed formula.
TRIAL REGISTRATION—clinicaltrials.gov Identifier: NCT00179777
Type 1 diabetes is characterized by selective loss of insulin-producing β cells in the 
pancreatic islets in genetically susceptible individuals. Overt clinical disable duration1 
during which diabetes-associated autoantibodies appear in the peripheral circulation as 
markers of emerging β-cell autoimmunity. Several disease-related autoantibodies predict 
clinical type 1 diabetes including classical islet cell antibodies (ICA), insulin autoantibodies, 
autoantibodies to glutamic acid decarboxylase (GAD), and the tyrosine phosphatase-related 
insulinoma-associated 2 molecule (IA-2).2 In natural history studies from infancy, positivity 
for at least 2 autoantibodies signals a risk of approximately 60% for the development of 
clinical diabetes over 10 years, whereas the 10-year risk among those with a single 
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autoantibody is about 15% and among those with no detectable autoantibodies less than 
1%.3
Accumulating evidence suggests that β-cell autoimmunity emerges early in life.4,5 The 
incidence of type 1 diabetes is increasing among children in Europe and North America,6,7 
although some studies suggest it may be stabilizing.8 This scenario implies that any measure 
aimed at primary prevention of type 1 diabetes, ie, prevention of the initiation of the diabetic 
disease process, has to be started in infancy. Early feeding may modify the risk of type 1 
diabetes later in life. Some epidemiological and immunological studies suggest that 
exposure to complex foreign proteins in early infancy may increase the risk of β-cell 
autoimmunity and type 1 diabetes in genetically susceptible individuals,9–11 although others 
do not.12,13 A pilot study suggested that weaning to an extensively hydrolyzed casein 
formula (99.7% of the generated peptides having a molecular weight of less than 2000 Da) 
decreased the cumulative incidence of diabetes-associated autoantibodies in children with an 
affected first-degree relative and a risk-associated HLA genotype.14,15 This led to TRIGR 
(Trial to Reduce IDDM in the Genetically at Risk), with the study powered to assess the 
effect of the intervention on the development of type 1 diabetes by age 10 years. A prior 
prespecified end point, early humoral β-cell autoimmunity, is reported herein.
Methods
Study Design
We conducted a randomized, double-blind study in 78 study centers in 15 countries (eTable 
1 in Supplement).16 Newborn infants who had a first-degree relative with type 1 diabetes 
were recruited between May 2002 and January 2007 and were observed to April 16, 2013, 
for this analysis. Randomization took place before birth or immediately after birth of the 
infants who met the inclusion criteria (Figure 1). The research assistant or investigator 
obtained the formula allocation code from the data management unit by completing the 
randomization form electronically. Randomization was balanced within each study center 
using a block size of 4. The randomization code will remain blinded to the participating 
families and all members of the study group, except for the data management and safety 
board and the principal investigator at the data management unit, until the study is 
completed in 2017. Written informed consent was obtained from the family before 
enrollment. The study was approved by the ethics committees of all participating centers. An 
agreement that the results would remain confidential until publication was in force between 
the members of the study group and Mead Johnson Nutrition, which provided the blinded 
color-coded study formulas.
Presentation of clinical type 1 diabetes by age 10 years is studied as the primary outcome 
while positivity for 2 or more islet autoantibodies by age 6 years is a secondary outcome.
Blood Samples
Cord blood samples and follow-up blood samples were obtained from the trial participants at 
ages 3, 6, 9, 12, 18, and 24 months, and thereafter annually up to age 10 years. Serum 
samples were stored at −70°C until analyzed.
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Dietary Intervention
Infants were randomly assigned weaning to either the experimental or control formulas that 
were produced specifically for this study. The experimental formula was an extensively 
hydrolyzed casein-based formula, while the control formula was composed of 80% intact 
cows’ milk protein and 20% hydrolyzed casein protein and formulated so that the taste and 
smell would be indistinguishable from the experimental formula. Study formulas were 
prepared and coded with the use of 4 colors by Mead Johnson. Newborn infants requiring 
supplemental feeding before randomization (eg, infants born at night or on weekends) 
received banked breast milk or Nutramigen.
Breastfeeding was practiced at the discretion of the participating mothers and maternal diets 
were unmodified. Breast-feeding was encouraged and exceeded national averages in both 
groups.17 The dietary intervention period lasted until the infant was at least 6 months of age, 
and if by that time the child had not received the study formula for at least 60 days, feeding 
of study formula was continued until 60 days of study formula exposure was reached, up to 
a maximum of 8 months of age. Parents were asked not to feed the infants any commercial 
or other baby foods containing bovine protein during the intervention period. Adherence to 
the protocol was monitored through regular family nutrition interviews (at age 0.5, 1, 2, 3, 4, 
5, 6, 7, and 8 months) and by the analysis of cows’-milk antibodies in serum samples.
HLA Genotyping
Cord blood or a heel-stick blood sample collected on filter paper was immediately sent to 
the Turku, Finland (Europe and Australia) or Pittsburgh, Pennsylvania (North America) 
laboratories for HLA genotyping. HLA genotyping for the selected DQB1 and DQA1 alleles 
was performed using sequence-specific oligonucleotide hybridization, with quality control 
between the 2 laboratories carefully maintained. The following genotypes were regarded as 
eligible: (1) HLADQB1*02/DQB1*03:02 (high risk); (2) HLA-DQB1*03: 02/x (x not 
DQB1*02, DQB1*03:01, or DQB1*06:02) (moderate risk); (3) HLADQA1*05-DQB1*02/y 
(y not DQA1*02:01-DQB1*02, DQB1*03:01, DQB1*06:02, or DQB1*06:03) (mild risk); 
(4) HLADQA1*03-DQB1*02/y (y not DQA1*02:01-DQB1*02, DQB1*03:01, 
DQB1*06:02, or DQB1*06:03) (rare mild risk).
β-Cell Autoimmunity and Cows’ Milk Antibody Assays
ICAs were detected using indirect immunofluorescence. The other 3 autoantibodies were 
quantified with the use of specific radiobinding assays in the Scientific Laboratory, 
Children’s Hospital, University of Helsinki, Helsinki, Finland, with cutoff limits for 
positivity of 2.5 Juvenile Diabetes Foundation units for ICAs, 2.80 relative units for insulin 
autoantibodies, 5.36 relative units for GAD autoantibodies, and 0.77 relative units for IA-2 
autoantibodies.18 The sensitivity and specificity for detecting existing type 1 diabetes of the 
assay for ICAs were 100% and 98%, respectively, in the fourth round of the international 
workshops on standardization of the ICA assay. The disease sensitivities and specificities of 
the assay for insulin autoantibodies were 44% and 98%, 82% and 97% for GAD 
autoantibodies, and 72% and 100% for IA-2 autoantibodies, respectively, in the 2005 
Diabetes Antibody Standardization Program workshop. Maternal antibodies that were 
placentally transferred, as verified by their decreasing levels and disappearance from the 
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infant’s circulation by age 18 months, were not included in the statistical analysis. Cows’ 
milk antibodies were measured from serum samples obtained from cord blood and at the age 
of 3, 6, and 9 months by enzyme-linked immunosorbent assay.
Statistical Analyses
The data management unit conducted the comparative analyses, as specified by protocol, 
when the unit had received the youngest child’s 6-year autoantibody results from the TRIGR 
core laboratory in Helsinki, Finland. The differences between the 2 groups with respect to 
the autoantibody titers and the duration of breastfeeding and study formula exposure were 
assessed using the Mann-Whitney U test. Statistical analyses were based on a longitudinal 
data set consisting of repeated measurements of several variables at standard time points. All 
statistical analyses were performed using SAS statistical software version 9.3.
Kaplan-Meier estimates and Cox proportional hazards regressions were used to analyze the 
association between the intervention and the risk of seroconversion to autoantibody 
positivity. The Cox regression analyses were adjusted for HLA risk, duration of 
breastfeeding, vitamin D use, study formula duration and consumption, and region (Finland, 
Canada, the United States, and other), as prespecified. The adjustment did not appreciably 
change the hazard ratio (HR), and therefore, the unadjusted log-rank test is the reported 
primary test of the end point.
The intention-to-treat principle was used for the analyses of seroconversion to autoantibody 
positivity. The analyses of seroconversion to autoantibody positivity were also performed 
according to treatment received (per-protocol analysis). A separate subanalysis of the 
Finnish participants (n = 424) was carried out as well. All tests were 2-tailed; P values of 
less than .05 were considered statistically significant. No imputations were performed due to 
missing values or loss to follow-up. Given a 95% CI and an estimated cumulative incidence 
of 2 or more autoantibodies of 9.9% by age 6 years in the control group, the study had a 
power of 80% to detect a 35% change in the end point, which represents a conservative 
estimate since a reduction in the cumulative incidence of multiple (≥2) antibodies in the 
range of 40% to 50% had been observed earlier in the TRIGR pilot.15 Similarly, the 
estimated cumulative incidence of at least 2 autoantibodies by age 6 years (9.9%) is a 
conservative estimate, since it represents the lower limit of the 95% CI for multiple 
autoantibody positivity among siblings in the Finnish DiMe study19 carrying the high-risk 
HLA genotype or one of the moderate-risk genotypes. The power of 80% results in 20% risk 
to miss a true difference between the groups.
Results
Altogether, 5606 potential participants were identified for the study during the 57 
recruitment months; 92% consented, resulting in 5156 newborn infants available for 
randomization before or immediately after birth (Figure 1). A sample for HLA genotyping 
was obtained from cord blood or if not available, from capillary blood taken within 7 days of 
birth. Inclusion criteria were not met by 156 randomized participants (3.0%), mainly owing 
to prematurity (gestational age <36 weeks up to June 4, 2003, and subsequently <35 weeks) 
or families changing their minds about study participation.
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Altogether, 2159 newborn infants (1142 boys [52.8%]) with an eligible HLA genotype 
(41.9% of the genotyped infants) continued in the intervention study. Five hundred sixteen 
infants (23.9%) carried the high-risk HLA genotype, 953 (44.1%) moderate-risk genotypes, 
668 (31.0%) mild-risk genotypes, and 22 (1.0%) the rare mild-risk genotype. The first-
degree relative with type 1 diabetes was the mother in 1055 infants (48.9%), the father in 
723 (33.5%), a sibling in 308 (14.3%), and more than 1 first-degree family member in 73 
participants (3.4%). The mean follow-up time for the detection of autoantibodies was 7.0 
years (median, 6.3 years; range, 3 months-10.3 years).
Randomization resulted in balanced groups with 1078 infants in the experimental group and 
1081 in the control group. There were no differences in the demographics or the distribution 
of HLA genotypes between the 2 groups (Table).
Study Intervention
In the experimental group, 80.0% of the infants vs 80.9% in the control group were exposed 
to the study formula during the intervention period. The mean (SD) ages of the infants at the 
time of study formula introduction were 2.0 months (95% CI, 1.8–2.1) in the experimental 
group and 1.8 months (95% CI, 1.6–1.9) in the control group (P = .05). The mean duration 
of study-formula feeding was 10.2 weeks (95% CI, 9.7–10.8) in the experimental group vs 
11.7 weeks (95% CI, 11.1–12.3) in the control group (P < .001). The mean per capita 
volumes of study formula consumed were 42.3 L (95% CI, 38.7–45.8) in the experimental 
group vs 48.7 L (95% CI, 45.1–52.4) in the control group (P = .01). The analysis of cows’ 
milk antibodies confirmed that the families adhered well with the dietary intervention 
resulting in clear differences in the antibody levels between the treatment groups (Figure 2).
β-Cell Autoimmunity
During the follow-up period, 2070 children (95.9%; 1035 in each group) provided at least 1 
blood sample for determination of diabetes-associated autoantibodies. The primary analysis 
of the autoantibody end point showed that 139 children in the experimental group (13.4%; 
95% CI, 11.3%–15.5%) tested positive for 2 or more autoantibodies, as compared with 117 
in the control group (11.3%; 95% CI, 9.4%–13.2%), At least 1 autoantibody developed in 
431 of the children in the experimental group (41.6%; 95% CI, 38.6%–44.6%) and in 414 in 
the control group (40.0%; 95% CI, 37.0%–43.0%). Altogether, 136 of the 256 participants 
with multiple autoantibodies (53.1%) had only 1 autoantibody in their first positive sample. 
Among those children, insulin autoantibodies were the first to appear in 47 children 
(34.6%), GAD antibodies in 46 (33.8%), ICAs in 41 (30.1%), and IA-2 antibodies in 2 
participants (1.5%). There was no difference between the 2 intervention groups regarding 
which autoantibody appeared first (eTable 3 in Supplement).
The earliest age at detection of autoantibodies was 3 months, and the latest seroconversion 
to date was at age 9 years. Among the children who tested positive for autoantibodies, there 
were no significant differences between the 2 treatment groups in the initial or maximal 
autoantibody titers (eTable 4 in Supplement). The cumulative incidences of at least 2 
autoantibodies and of at least 1 autoantibody in the experimental and control groups by age 
at first detection are shown as parametric maximum-likelihood estimates in Figure 3. The 
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cumulative incidences of each individual autoantibody in the 2 groups are presented in 
Figure 4. The corresponding cumulative incidences based on the per-protocol analyses are 
shown in eFigure 1 and eFigure 2 in the Supplement. The observed trends in the HRs were 
in the opposite direction when compared with the hypothesized benefit of the experimental 
formula. The unadjusted HR for positivity for 2 or more autoantibodies was 1.21 (95% CI, 
0.94–1.54), while the adjusted HR for HLA risk, duration of breastfeeding, vitamin D use, 
study formula duration and consumption, and region was 1.23 (95% CI, 0.96–1.58). The 
unadjusted HR for positivity for 1 or more autoantibodies was 1.06 (95% CI, 0.93–1.22), 
whereas the adjusted HR was 1.09 (95% CI, 0.95–1.24). The subanalysis of the 424 Finnish 
participants showed an unadjusted HR of 1.20 (95% CI, 0.71–2.05; eFigure 3 in 
Supplement), whereas the adjusted HR for HLA risk, duration of breastfeeding, vitamin D 
use, and study formula duration and consumption was 1.33 (95% CI, 0.77–2.29).
Adverse Events
The children in the experimental group had a slightly lower rate of middle ear infections 
(eTable 5 in Supplement) when compared with children in the the control group (P = .04). 
Similar linear growth and weight gain were observed in both groups. There were no 
significant differences between the 2 groups in the rate of other adverse events during the 
total follow-up time.
Discussion
This study showed that in this large international trial in children with an HLA genotype 
conferring increased risk for type 1 diabetes and an affected first-degree relative, weaning to 
a highly hydrolyzed formula during infancy was not associated with any reduction in the 
signs of cumulative β-cell autoimmunity. This outcome is in contrast to data from the 
TRIGR pilot study,15 which reported that weaning to an extensively hydrolyzed formula in 
infancy was associated with an almost 50% reduction in the cumulative incidence of β-cell 
autoimmunity by the age of 10 years in similar children. The TRIGR pilot study was 
conducted in 230 Finnish children, while the current trial targets 2159 high-risk children 
from 15 different countries, the majority of the participants being from Canada, Finland, and 
United States.
The reasons for the discrepancy between the 2 studies are unclear. The large TRIGR study 
provides substantially stronger statistical power, although it includes a more heterogeneous 
study population than the pilot study. The proportion of children with a father with type 1 
diabetes was about 10% higher in the pilot study compared with the large-scale trial (43% vs 
34%). Although it is well established that the risk of type 1 diabetes is approximately 2 
times higher among offspring of affected fathers than of affected mothers,20 this relatively 
small difference cannot explain the divergent results. The subanalysis of the 424 Finnish 
participants in the current trial showed that the results were very close to those seen in the 
total study cohort. Accordingly, it is unlikely that heterogeneity between the various 
populations involved in the TRIGR study would explain the contrasting outcome of the pilot 
study and this larger study. The pilot trial may have yielded a false-positive result.
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The strengths of the current trial encompass a very high retention rate of the participants and 
documented dietary adherence. The fact that the study was performed in 15 countries on 3 
continents also supports the generalizability of the results. The TRIGR study was planned to 
have 2 end points, ie, positivity for 2 autoantibodies by age 6 years and clinical diabetes by 
the age of 10 years. An important consideration is whether there is any justification to 
continue the follow-up of the trial participants given the current results. A recent 
combination of 3 natural history studies, ie, the Finnish DIPP study, the German 
BABYDIAB study, and the American DAISY study, has shown that positivity for 2 or more 
autoantibodies is associated with a risk of progression to clinical diabetes over the next 10 
years of approximately 60% and approximately 80% over 15 years with variable rates of 
progression.3 Despite this, there is justification to continue the observation of the TRIGR 
children in order to analyze the study end point, which is clinical diabetes when the 
youngest child reaches 10 years in 3-years’ time. First, TRIGR is not a natural history study 
but an intervention trial, and the intervention may affect progression from islet 
autoimmunity to clinical disease. Such a scenario has been observed in nonobese diabetic 
mice, in which administration of an extensively hydrolyzed casein formula after weaning 
reduced the rate of autoimmune diabetes considerably with little effect on islet inflammation 
and autoimmunity.21 Second, the planned study was powered to detect the development of 
diabetes as the relevant end point. Third, the continued observation provides an opportunity 
to assess whether and how puberty may modify the progression to clinical disease.
This study has several limitations. The study participants were selected based on a positive 
family history for type 1 diabetes and an HLA genotype conferring risk for type 1 diabetes. 
Accordingly, the results are not directly generalizable to the background population. This 
study was not designed to test the effect of breastfeeding since random assignment of infants 
to breastfeeding or formula feeding would not be ethical. So far, we have not detected any 
effect of exclusive breastfeeding. Some prospective studies assessing the associations 
between infant feeding patterns and the development of β-cell autoimmunity in children who 
are at genetic risk for type 1 diabetes have not observed any associations between the 
duration of either exclusive or total breastfeeding and β-cell autoimmunity.10,11 However, a 
single-cohort study involving children in the general population showed that a shorter 
duration of breastfeeding was related to an increased risk of positivity for GAD 
autoantibodies, insulin autoantibodies, or both.22
The casein-based formula used as the intervention modality in this study is highly 
hydrolyzed and does not contain intact proteins. Less than 0.3% of the peptides have a 
molecular weight exceeding 2000 daltons. Accordingly, the formula is free of intact bovine 
insulin, which is present in cows’ milk.23 In a study by Vaarala et al,24 results showed that 
infants fed a conventional cows’ milk–based formula before the age of 3 months developed 
a strong immune response to bovine insulin, which differs from human insulin by 3 amino 
acids. Infants developing early signs of β-cell autoimmunity lacked the capacity to mount 
oral tolerance to bovine insulin. Sustained bovine insulin immunity might contribute to 
prediabetes progression, as weaning to an insulin-free formula reduced the cumulative 
incidence of autoantibodies by more than half in young children at genetic risk for type 1 
diabetes.25
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Our experience shows that a large-scale primary preventive dietary intervention aimed at 
decreasing the risk of type 1 diabetes is feasible. In contrast to the pilot study and supportive 
animal and uncontrolled human studies, weaning to a hydrolyzed formula in early infancy 
had no effect on the development of β-cell autoimmunity. It is, however, possible that the 
hydrolyzed formula affects the degree and rate of progression of autoimmunity to clinical 
diabetes in high-risk children, which will be ascertained in the TRIGR cohort by the 10-year 
follow-up. At the time of this publication, there is, however, no conclusive evidence to 
revise the current dietary recommendations for infants at high risk for type 1 diabetes.
Conclusions
Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula compared with a 
conventional formula did not reduce the incidence of diabetes-associated autoantibodies 
after 7 years of follow-up. These findings do not support a benefit from hydrolyzed formula.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Screening, Randomization, and Follow-up of TRIGR Study Infants
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Figure 2. Cows’ Milk Antibody Titers Over the First 9 Months of Life
IgG (Panels A and B) and IgA (Panels C and D) class antibodies to cows’ milk (infant 
formula) in cord blood and at the ages of 3, 6, and 9 months in the casein hydrolysate group 
and control group. The bottom of the box plots indicate the 25th percentile and the top the 
75th percentile. The circle symbols indicate the mean. The lower end of the whiskers 
represent the minimum observation and the upper end the maximum observation below the 
upper fence (1.5 interquartile range above the 75th percentile).
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Figure 3. Cumulative Survival Without at Least 2 Autoantibodies and at Least 1 Autoantibody
The cumulative survival without at least 2 autoantibodies (Panel A) and without at least 1 
autoantibody (Panel B) is shown for the casein hydrolysate group and the control group 
according to the age of the children at the time the autoantibodies were detected.
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Figure 4. Cumulative Survival Without Islet Cell Antibodies, Insulin Autoantibodies, and 
Autoantibodies to Glutamic Acid Decarboxylase (GAD) and the Insulinoma-Associated–2 
Molecule (IA-2)
The cumulative survival without islet cell antibodies (Panel A), insulin autoantibodies 
(Panel B), GAD antibodies (Panel C), and IA-2 autoantibodies (Panel D) is shown for the 
casein hydrolysate group and the control group according to the age of the children at the 
time the autoantibodies were detected.
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Table
Demographic Characteristics of the Trial Participants
Characteristics
No. (%)
Casein Hydrolysate (n = 1081) Control (n = 1078)
Male sex 576 (53.3) 565 (52.4)
Gestational age, mean (SD), wk 38.7 (1.6) 38.8 (1.6)
Birth weight, mean (SD), g 3585 (539) 3625 (558)
Birth length, mean (SD), cm 50.9 (2.8) 51.1 (2.8)
Family history of type 1 diabetes
 Mother 531 (49.1) 524 (48.6)
 Father 356 (32.9) 367 (34.0)
 Sibling 151 (14.0) 157 (14.6)
 More than one family member 43 (4.0) 30 (2.8)
HLA genotype
 HLADQB1*02/DQB1*0302 260 (24.1) 256 (23.7)
 HLA-DQB1*0302/x (x not DQB1*02, DQB1*0301, or DQB1*0602) 478 (44.2) 475 (44.1)
 HLA-DQA1*05-DQB1*02/y (y not DQA1*0201-DQB1*02, DQB1*0301, 
DQB1*0602, or DQB1*0603)
332 (30.7) 336 (31.2)
 HLA-DQA1*03-DQB1*02/y (y not DQA1*0201-DQB1*02, DQB1*0301, 
DQB1*0602, or DQB1*0603)
11 (1.0) 11 (1.0)
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